CalciMedica, Inc. (NASDAQ:CALC – Get Free Report) insider Eric W. Roberts acquired 5,000 shares of the stock in a transaction dated Thursday, June 27th. The stock was bought at an average cost of $3.22 per share, with a total value of $16,100.00. Following the completion of the purchase, the insider now owns 10,223 shares of the company’s stock, valued at $32,918.06. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.
CalciMedica Stock Performance
NASDAQ CALC traded up $0.81 on Friday, hitting $3.96. 244,715 shares of the stock traded hands, compared to its average volume of 29,052. The business’s fifty day moving average is $5.27 and its two-hundred day moving average is $4.60. CalciMedica, Inc. has a 12 month low of $1.75 and a 12 month high of $8.38. The firm has a market capitalization of $42.57 million, a price-to-earnings ratio of -1.81 and a beta of 1.35.
CalciMedica (NASDAQ:CALC – Get Free Report) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.07. Analysts expect that CalciMedica, Inc. will post -2.05 EPS for the current fiscal year.
Hedge Funds Weigh In On CalciMedica
Analyst Ratings Changes
Several equities analysts have recently issued reports on the company. Oppenheimer reaffirmed an “outperform” rating and issued a $14.00 target price on shares of CalciMedica in a report on Monday, April 1st. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of CalciMedica in a report on Thursday.
Check Out Our Latest Report on CalciMedica
About CalciMedica
CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Recommended Stories
- Five stocks we like better than CalciMedica
- Why Invest in 5G? How to Invest in 5G Stocks
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- Are Penny Stocks a Good Fit for Your Portfolio?
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- Stock Average Calculator
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.